Reblozyl (luspatercept-aamt) 25mg Injection

How It Works

Reblozyl (luspatercept-aamt) is an erythroid maturation agent (EMA) that works by binding to select transforming growth factor-beta (TGF-?) superfamily ligands. This binding reduces Smad2/3 signaling, which enhances late-stage erythropoiesis (the process of red blood cell formation). By promoting the maturation of erythroid precursors, Reblozyl increases hemoglobin levels and reduces the need for red blood cell transfusions in patients with specific types of anemia.

List of Side Effects

• Fatigue
• Headache
• Muscle and bone pain
• Arthralgia (joint pain)
• Dizziness
• Hypertension (high blood pressure)
• Upper respiratory tract infections
• Diarrhea
• Nausea
• Abdominal pain

List of Indications

• Treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions
• Treatment of anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts who have failed an erythropoiesis stimulating agent (ESA) and require 2 or more RBC units over 8 weeks

List of Contraindications

• Hypersensitivity to luspatercept-aamt or any of the excipients in Reblozyl
• Pregnancy
• Women who are breastfeeding

Price in Different Countries

Country	Price (USD)	Reference Website
United States	$10,000	GoodRx
United Kingdom	?7,500	NICE BNF
Canada	$13,000 CAD	CanadaDrugs.com
Australia	$14,500 AUD	PBS Australia
India	?750,000 INR	1mg
Pakistan	? 1,600,000 PKR	Dawaai.pk

Top 5 Global Brands

1. Reblozyl (Luspatercept-aamt) – Bristol Myers Squibb
2. Jivi (BAY94-9027) – Bayer
3. Oxbryta (Voxelotor) – Global Blood Therapeutics
4. Adakveo (Crizanlizumab) – Novartis
5. Hydrea (Hydroxyurea) – Bristol Myers Squibb